On July 17, 2025 Abbott (NYSE: ABT) reported financial results for the second quarter ended June 30, 2025 (Press release, Abbott, JUL 17, 2025, View Source [SID1234654420]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Second-quarter sales increased 7.4 percent on a reported basis, 6.9 percent on an organic basis, or 7.5 percent when excluding COVID-19 testing-related sales1.
Second-quarter GAAP diluted EPS of $1.01 and adjusted diluted EPS of $1.26, which excludes specified items and reflects double-digit growth compared to the prior year.
First-half sales increased 5.7 percent on a reported basis, 6.9 percent on an organic basis, or 7.9 percent when excluding COVID-19 testing-related sales2.
Abbott projects full-year 2025 organic sales growth, excluding COVID-19 testing-related sales, to be 7.5% to 8.0%, or 6.0% to 7.0% when including COVID-19 testing-related sales.
Abbott projects full-year 2025 adjusted diluted EPS of $5.10 to $5.20, which reflects double-digit growth at the midpoint.
In April, Abbott completed enrollment ahead of schedule in its FlexPulse U.S. IDE trial, which is designed to evaluate the TactiFlex Duo Pulsed Field Ablation (PFA) System for treating patients with heart rhythm disorders such as atrial fibrillation (AFib).
In April, Abbott announced late-breaking data from the AVEIR Conduction System Pacing (CSP) clinical feasibility study. This study was the world’s first assessment of a leadless pacemaker delivering conduction pacing, which produces pacing that closely mimics the heart’s natural electrical rhythm and represents a new treatment option for people with irregular heart rhythms.
In May, Abbott announced U.S. Food and Drug Administration (FDA) approval of the company’s Tendyne transcatheter mitral valve replacement (TMVR) system, a first-of-its-kind device to help treat people with mitral valve disease.
Abbott has initiated plans to develop a new cardiovascular device manufacturing facility in the state of Georgia to be completed by 2028.
"Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly expanded our margin profiles, and continued to advance key programs through our new product pipeline," said Robert B. Ford, chairman and chief executive officer, Abbott. "We see this momentum carrying into 2026."
SECOND-QUARTER BUSINESS OVERVIEW
Management believes that measuring sales growth rates on an organic basis, which excludes the impact of foreign exchange and the impact of discontinuing the ZonePerfect product line in the Nutrition business, is an appropriate way for investors to best understand the core underlying performance of the business. Management further believes thatmeasuring sales growth rates on an organic basis excluding COVID-19 tests is an appropriate way for investors to bestunderstand the underlying performance of the company as the demand for COVID-19 tests has significantly declined following the transition from a pandemic to endemic phase.
Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.
Second Quarter 2025 Results (2Q25)
Sales 2Q25 ($ in millions)
Total Company
Nutrition
Diagnostics
Established
Pharmaceuticals
Medical Devices
U.S.
4,276
957
811
—
2,503
International
6,866
1,255
1,362
1,383
2,866
Total reported
11,142
2,212
2,173
1,383
5,369
% Change vs. 2Q24
U.S.
8.7
2.6
(0.1)
n/a
14.6
International
6.6
3.1
(1.5)
6.9
12.4
Total reported
7.4
2.9
(1.0)
6.9
13.4
Impact of foreign exchange
0.5
(0.5)
0.4
(0.8)
1.2
Organic
6.9
3.4
(1.4)
7.7
12.2
Impact of COVID-19 testing sales 1
(0.6)
—
(2.2)
—
—
Organic (excluding COVID-19 tests)
7.5
3.4
0.8
7.7
12.2
Organic
U.S.
8.7
2.6
(0.1)
n/a
14.6
International
5.8
4.0
(2.2)
7.7
10.1
First Half 2025 Results (1H25)
Sales 1H25 ($ in millions)
Total Company
Nutrition
Diagnostics
Established
Pharmaceuticals
Medical Devices
U.S.
8,444
1,912
1,682
—
4,842
International
13,056
2,446
2,545
2,643
5,422
Total reported
21,500
4,358
4,227
2,643
10,264
% Change vs. 1H24
U.S.
8.5
5.6
(3.5)
n/a
14.8
International
3.9
1.6
(4.5)
4.9
9.1
Total reported
5.7
3.3
(4.1)
4.9
11.7
Impact of foreign exchange
(1.1)
(1.5)
(0.9)
(2.9)
(0.7)
Impact of business exit*
(0.1)
(0.3)
—
—
—
Organic
6.9
5.1
(3.2)
7.8
12.4
Impact of COVID-19 testing sales 2
(1.0)
—
(3.9)
—
—
Organic (excluding COVID-19 tests)
7.9
5.1
0.7
7.8
12.4
Organic
U.S.
8.7
6.4
(3.5)
n/a
14.8
International
5.8
4.1
(3.0)
7.8
10.3
Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of adjusted historical revenue to reported revenue.
*Reflects the impact of discontinuing the ZonePerfect product line in the Nutrition business in March 2024.
Nutrition
Second Quarter 2025 Results (2Q25)
Sales 2Q25 ($ in millions)
Total
Pediatric
Adult
U.S.
957
587
370
International
1,255
467
788
Total reported
2,212
1,054
1,158
% Change vs. 2Q24
U.S.
2.6
4.2
0.2
International
3.1
(5.7)
9.2
Total reported
2.9
(0.4)
6.1
Impact of foreign exchange
(0.5)
(0.6)
(0.5)
Organic
3.4
0.2
6.6
U.S.
2.6
4.2
0.2
International
4.0
(4.5)
9.8
Worldwide Nutrition sales increased 2.9 percent on a reported basis and 3.4 percent on an organic basis in the second quarter.
Growth in the quarter was led by Adult Nutrition, where global sales increased 6.1 percent on a reported basis and 6.6 percent on an organic basis, led by strong growth of Ensure, Abbott’s market-leading complete and balanced nutrition brand, and Glucerna, Abbott’s market-leading brand of products designed to meet the nutritional requirements for people with diabetes.
First Half 2025 Results (1H25)
Sales 1H25 ($ in millions)
Total
Pediatric
Adult
U.S.
1,912
1,175
737
International
2,446
920
1,526
Total reported
4,358
2,095
2,263
% Change vs. 1H24
U.S.
5.6
9.0
0.6
International
1.6
(7.0)
7.7
Total reported
3.3
1.3
5.3
Impact of foreign exchange
(1.5)
(1.2)
(1.6)
Impact of business exit*
(0.3)
—
(0.7)
Organic
5.1
2.5
7.6
U.S.
6.4
9.0
2.4
International
4.1
(4.6)
10.2
*Reflects the impact of discontinuing the ZonePerfect product line in the Nutrition business in March 2024.
Diagnostics
Second Quarter 2025 Results (2Q25)
Sales 2Q25 ($ in millions)
Total
Core Laboratory
Molecular
Point of Care
Rapid
Diagnostics
U.S.
811
351
35
104
321
International
1,362
1,007
88
44
223
Total reported
2,173
1,358
123
148
544
% Change vs. 2Q24
U.S.
(0.1)
7.3
5.5
(2.0)
(7.1)
International
(1.5)
0.5
(5.6)
(11.9)
(6.1)
Total reported
(1.0)
2.2
(2.7)
(5.1)
(6.7)
Impact of foreign exchange
0.4
0.6
0.7
0.1
0.1
Organic
(1.4)
1.6
(3.4)
(5.2)
(6.8)
U.S.
(0.1)
7.3
5.5
(2.0)
(7.1)
International
(2.2)
(0.3)
(6.5)
(12.1)
(6.3)
Global Diagnostics sales decreased 1.0 percent on a reported basis, decreased 1.4 percent on an organic basis, and increased 0.8 percent when excluding COVID-19 testing-related sales1.
Diagnostics sales growth was impacted by the year-over-year decline in COVID-19 testing-related sales and volume-based procurement programs in China.
COVID-19 testing-related sales were $55 million in the quarter, compared to $102 million in the second quarter of the prior year.
Global Core Laboratory Diagnostics sales increased 2.2 percent on a reported basis and increased 1.6 percent on an organic basis. Growth in the quarter was impacted by volume-based procurement programs in China.
First Half 2025 Results (1H25)
Sales 1H25 ($ in millions)
Total
Core Laboratory
Molecular
Point of Care
Rapid
Diagnostics
U.S.
1,682
683
75
204
720
International
2,545
1,852
170
86
437
Total reported
4,227
2,535
245
290
1,157
% Change vs. 1H24
U.S.
(3.5)
7.2
—
(0.3)
(12.8)
International
(4.5)
(2.4)
(6.1)
(4.5)
(12.3)
Total reported
(4.1)
0.1
(4.4)
(1.6)
(12.6)
Impact of foreign exchange
(0.9)
(1.2)
(1.0)
(0.4)
(0.6)
Organic
(3.2)
1.3
(3.4)
(1.2)
(12.0)
U.S.
(3.5)
7.2
—
(0.3)
(12.8)
International
(3.0)
(0.7)
(4.9)
(3.3)
(10.7)
Established Pharmaceuticals
Second Quarter 2025 Results (2Q25)
Sales 2Q25 ($ in millions)
Total
Key Emerging
Markets
Other
U.S.
—
—
—
International
1,383
1,059
324
Total reported
1,383
1,059
324
% Change vs. 2Q24
U.S.
n/a
n/a
n/a
International
6.9
7.3
5.9
Total reported
6.9
7.3
5.9
Impact of foreign exchange
(0.8)
(1.4)
1.4
Organic
7.7
8.7
4.5
U.S.
n/a
n/a
n/a
International
7.7
8.7
4.5
Established Pharmaceuticals sales increased 6.9 percent on a reported basis and 7.7 percent on an organic basis in the second quarter.
Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott’s branded generics product portfolio. Sales in these geographies increased 7.3 percent on a reported basis and 8.7 percent on an organic basis, led by double-digit growth in several countries across Asia, Latin America and the Middle East.
First Half 2025 Results (1H25)
Sales 1H25 ($ in millions)
Total
Key Emerging
Markets
Other
U.S.
—
—
—
International
2,643
2,024
619
Total reported
2,643
2,024
619
% Change vs. 1H24
U.S.
n/a
n/a
n/a
International
4.9
5.7
2.4
Total reported
4.9
5.7
2.4
Impact of foreign exchange
(2.9)
(3.3)
(1.4)
Organic
7.8
9.0
3.8
U.S.
n/a
n/a
n/a
International
7.8
9.0
3.8
Medical Devices
Second Quarter 2025 Results (2Q25)
Sales 2Q25 ($ in millions)
Total
Rhythm
Management
Electro-
physiology
Heart
Failure
Vascular
Structural
Heart
Neuro-
modulation
Diabetes
Care
U.S.
2,503
340
322
282
283
289
193
794
International
2,866
333
378
86
474
347
61
1,187
Total reported
5,369
673
700
368
757
636
254
1,981
% Change vs. 2Q24
U.S.
14.6
16.5
12.2
15.8
3.0
12.2
0.4
24.5
International
12.4
5.7
10.9
11.2
5.4
13.7
20.4
17.5
Total reported
13.4
10.9
11.5
14.7
4.5
13.0
4.6
20.2
Impact of foreign exchange
1.2
1.1
1.2
0.7
1.0
1.3
0.3
1.7
Organic
12.2
9.8
10.3
14.0
3.5
11.7
4.3
18.5
U.S.
14.6
16.5
12.2
15.8
3.0
12.2
0.4
24.5
International
10.1
3.6
8.8
8.4
3.8
11.4
18.7
14.7
Worldwide Medical Devices sales increased 13.4 percent on a reported basis and 12.2 percent on an organic basis in the second quarter.
Sales growth in the quarter was led by double-digit growth in Diabetes Care, Heart Failure, Structural Heart and Electrophysiology.
Several products contributed to the strong performance, including FreeStyle Libre, Navitor, TriClip and AVEIR.
In Diabetes Care, sales of continuous glucose monitors were $1.9 billion and grew 21.4 percent on a reported basis and 19.6 percent on an organic basis.
First Half 2025 Results (1H25)
Sales 1H25 ($ in millions)
Total
Rhythm
Management
Electro-
physiology
Heart
Failure
Vascular
Structural
Heart
Neuro-
modulation
Diabetes
Care
U.S.
4,842
644
621
544
551
571
369
1,542
International
5,422
614
708
163
916
642
113
2,266
Total reported
10,264
1,258
1,329
707
1,467
1,213
482
3,808
% Change vs. 1H24
U.S.
14.8
14.4
11.7
13.2
4.2
16.3
(1.1)
25.7
International
9.1
1.2
7.6
12.6
3.5
9.3
18.5
13.8
Total reported
11.7
7.6
9.5
13.1
3.8
12.5
2.9
18.4
Impact of foreign exchange
(0.7)
(0.4)
(0.6)
(0.2)
(0.7)
(0.7)
(0.4)
(0.7)
Organic
12.4
8.0
10.1
13.3
4.5
13.2
3.3
19.1
U.S.
14.8
14.4
11.7
13.2
4.2
16.3
(1.1)
25.7
International
10.3
2.0
8.8
13.4
4.8
10.5
20.5
15.0
ABBOTT’S FINANCIAL GUIDANCE
Abbott projects full-year 2025 organic sales growth, excluding COVID-19 testing related sales, to be 7.5% to 8.0%, or 6.0% to 7.0% when including COVID-19 testing-related sales.
Abbott projects full-year 2025 adjusted operating margin to be approximately 23.5% of sales.
Abbott projects full-year 2025 adjusted diluted earnings per share of $5.10 to $5.20 and third-quarter 2025 adjusted diluted earnings per share of $1.28 to $1.32.
Abbott has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition-related expenses, and foreign exchange, which could significantly impact Abbott’s results in accordance with GAAP.
ABBOTT DECLARES 406th CONSECUTIVE QUARTERLY DIVIDEND
On June 13, 2025, the board of directors of Abbott declared the company’s quarterly dividend of $0.59 per share. Abbott’s cash dividend is payable Aug. 15, 2025, to shareholders of record at the close of business on July 15, 2025.
Abbott has increased its dividend payout for 53 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.